LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net sales

Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net sales